Samalizumab - Alexion Pharmaceuticals

Drug Profile

Samalizumab - Alexion Pharmaceuticals

Alternative Names: ALXN 6000

Latest Information Update: 07 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alexion Pharmaceuticals
  • Developer Alexion Pharmaceuticals; The Leukemia & Lymphoma Society
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD200 antigen inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia
  • Phase I Solid tumours
  • Discontinued Chronic lymphocytic leukaemia; Multiple myeloma

Most Recent Events

  • 01 Sep 2017 Alexion Pharmaceuticals terminates phase I trial in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT02987504)
  • 03 Aug 2017 Alexion Pharmaceuticals suspends patient enrolment in a phase I trial in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT02987504)
  • 27 Jul 2017 Samalizumab is available for licensing as of 27 Jul 2017. http://ir.alexionpharm.com/releasedetail.cfm?ReleaseID=1034669
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top